Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QDEL Stock Forecast 2025-2026
$27.77
Current Price
$1.89B
Market Cap
Buy 3
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to QDEL Price Targets
+116.1%
To High Target of $60.00
+18.8%
To Median Target of $33.00
-20.8%
To Low Target of $22.00
QDEL Price Momentum
+1.5%
1 Week Change
+36.5%
1 Month Change
-27.3%
1 Year Change
-37.7%
Year-to-Date Change
-43.8%
From 52W High of $49.45
+42.4%
From 52W Low of $19.50
📊 TOP ANALYST CALLS
Did QDEL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Quidel is one of their latest high-conviction picks.
Latest QDEL Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, QDEL has a neutral consensus with a median price target of $33.00 (ranging from $22.00 to $60.00). The overall analyst rating is N/A (N/A/10). Currently trading at $27.77, the median forecast implies a 18.8% upside. This outlook is supported by 3 Buy, 3 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Casey Woodring at JP Morgan, suggesting a 20.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QDEL Analyst Ratings
3
Buy
3
Hold
1
Sell
QDEL Price Target Range
Low
$22.00
Average
$33.00
High
$60.00
Current: $27.77
Latest QDEL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QDEL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 7, 2025 | JP Morgan | Casey Woodring | Underweight | Maintains | $22.00 |
| Nov 6, 2025 | UBS | Lu Li | Neutral | Maintains | $31.00 |
| Oct 7, 2025 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $33.00 |
| Aug 7, 2025 | UBS | Lu Li | Neutral | Maintains | $26.00 |
| Aug 6, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $40.00 |
| May 8, 2025 | UBS | Lu Li | Neutral | Maintains | $29.00 |
| May 8, 2025 | Jefferies | Tycho Peterson | Buy | Upgrade | $44.00 |
| Apr 21, 2025 | JP Morgan | Casey Woodring | Underweight | Maintains | $25.00 |
| Feb 13, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $61.00 |
| Feb 13, 2025 | UBS | John Sourbeer | Neutral | Maintains | $45.00 |
| Dec 11, 2024 | Citigroup | Patrick Donnelly | Buy | Upgrade | $50.00 |
| Dec 10, 2024 | Jefferies | Tycho Peterson | Hold | Initiates | $43.00 |
| Sep 19, 2024 | UBS | John Sourbeer | Neutral | Upgrade | $50.00 |
| Sep 5, 2024 | Craig-Hallum | Alexander Nowak | Buy | Upgrade | $57.00 |
| Aug 16, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $61.00 |
| Aug 1, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $61.00 |
| May 9, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $68.00 |
| Mar 4, 2024 | UBS | John Sourbeer | Sell | Downgrade | $42.00 |
| Feb 14, 2024 | Raymond James | Andrew Cooper | Outperform | Downgrade | $76.00 |
| Feb 14, 2024 | William Blair | Andrew Brackmann | Market Perform | Downgrade | $N/A |
QuidelOrtho Corporation (QDEL) Competitors
The following stocks are similar to Quidel based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
QuidelOrtho Corporation (QDEL) Financial Data
QuidelOrtho Corporation has a market capitalization of $1.89B with a P/E ratio of -0.9x. The company generates $2.71B in trailing twelve-month revenue with a -43.5% profit margin.
Revenue growth is -3.7% quarter-over-quarter, while maintaining an operating margin of +6.7% and return on equity of -45.2%.
Valuation Metrics
Market Cap
$1.89B
Enterprise Value
$4.65B
P/E Ratio
-0.9x
PEG Ratio
0.0x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
-3.7%
Gross Margin
+47.9%
Operating Margin
+6.7%
Net Margin
-43.5%
EPS Growth
-3.7%
Financial Health
Cash/Price Ratio
+5.2%
Current Ratio
1.8x
Debt/Equity
140.7x
ROE
-45.2%
ROA
+1.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
QuidelOrtho Corporation (QDEL) Business Model
About QuidelOrtho Corporation
What They Do
Manufactures diagnostic testing solutions for healthcare.
Business Model
QuidelOrtho Corporation generates revenue by developing and providing a wide range of diagnostic products, including rapid tests and laboratory assays, that cater to various medical conditions. Their products are utilized in clinical laboratories, hospitals, and primary care settings, ensuring a steady demand from healthcare providers seeking timely and accurate diagnostic solutions.
Additional Information
The company plays a vital role in the healthcare sector, particularly during health crises, by fulfilling the increased demand for reliable testing solutions. QuidelOrtho's focus on innovative diagnostic technologies positions it as a key player in improving public health outcomes across diverse medical areas.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
6,600
CEO
Mr. Brian J. Blaser
Country
United States
IPO Year
1992
Website
www.quidelortho.comQuidelOrtho Corporation (QDEL) Latest News & Analysis
Latest News
QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
4 days ago
Quick Summary
QuidelOrtho Corporation (QDEL) presented at the Citi Annual Global Healthcare Conference 2025, sharing updates relevant to investors and stakeholders in the healthcare sector.
Why It Matters
QuidelOrtho's presentation at a major conference signals potential updates on growth, innovations, or partnerships, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
QuidelOrtho Corporation (Nasdaq: QDEL) will participate in the Evercore ISI 8th Annual Healthcare Conference on December 2, 2025, with a management fireside chat at 10:00 a.m. ET.
Why It Matters
QuidelOrtho's participation in investor conferences signals engagement with the investment community, potentially impacting stock interest and market perceptions of its growth and strategy.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
QuidelOrtho Corporation released a new episode of its Science Bytes podcast featuring Dr. Qian Ding discussing the importance of early diabetes detection for clinical and economic benefits.
Why It Matters
QuidelOrtho's focus on early diabetes detection highlights potential market growth in diagnostics, impacting revenue prospects and competitive positioning, which can influence stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
QuidelOrtho Corporation (QDEL) will host its Q3 2025 earnings call on November 5, 2025, at 5:00 PM EST, featuring key executives and financial analysts.
Why It Matters
QuidelOrtho's Q3 2025 earnings call will reveal financial performance and strategic insights, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
QuidelOrtho reported Q3 2025 revenue of $700 million, with non-respiratory revenue up 5%. They completed debt refinancing and narrowed guidance for 2025, adjusting diluted EPS to $0.80.
Why It Matters
QuidelOrtho's solid revenue growth and successful debt refinancing enhance financial flexibility, while narrowed guidance indicates management's confidence, impacting investor sentiment positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
QDEL exceeded Q3 estimates, driven by growth in Labs and Immunohematology units, with strengthening margins despite a decline in respiratory revenue.
Why It Matters
QDEL exceeding Q3 estimates indicates strong operational performance, suggesting resilience and potential for future growth, which may boost investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About QDEL Stock
What is QuidelOrtho Corporation's (QDEL) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, QuidelOrtho Corporation (QDEL) has a median price target of $33.00. The highest price target is $60.00 and the lowest is $22.00.
Is QDEL stock a good investment in 2026?
According to current analyst ratings, QDEL has 3 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $27.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QDEL stock?
Wall Street analysts predict QDEL stock could reach $33.00 in the next 12 months. This represents a 18.8% increase from the current price of $27.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is QuidelOrtho Corporation's business model?
QuidelOrtho Corporation generates revenue by developing and providing a wide range of diagnostic products, including rapid tests and laboratory assays, that cater to various medical conditions. Their products are utilized in clinical laboratories, hospitals, and primary care settings, ensuring a steady demand from healthcare providers seeking timely and accurate diagnostic solutions.
What is the highest forecasted price for QDEL QuidelOrtho Corporation?
The highest price target for QDEL is $60.00 from at , which represents a 116.1% increase from the current price of $27.77.
What is the lowest forecasted price for QDEL QuidelOrtho Corporation?
The lowest price target for QDEL is $22.00 from Casey Woodring at JP Morgan, which represents a -20.8% decrease from the current price of $27.77.
What is the overall QDEL consensus from analysts for QuidelOrtho Corporation?
The overall analyst consensus for QDEL is neutral. Out of 15 Wall Street analysts, 3 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $33.00.
How accurate are QDEL stock price projections?
Stock price projections, including those for QuidelOrtho Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 1:37 PM UTC